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Nanocarriers take advantages of the enhanced permeability and retention (EPR) to accumulate passively
in solid tumors. Magnetic targeting has shown to further enhance tumor accumulation in response to a
magnetic ﬁeld gradient. It is widely known that passive accumulation of nanocarriers varies hugely in
tumor tissues of different tumor vascularization. It is hypothesized that magnetic targeting is likely to be
inﬂuenced by such factors. In this work, magnetic targeting is assessed in a range of subcutaneously
implanted murine tumors, namely, colon (CT26), breast (4T1), lung (Lewis lung carcinoma) cancer and
melanoma (B16F10). Passively- and magnetically-driven tumor accumulation of the radiolabeled poly-
meric magnetic nanocapsules are assessed with gamma counting. The inﬂuence of tumor vasculature,
namely, the tumor microvessel density, permeability and diameter on passive and magnetic tumor
targeting is assessed with the aid of the retrospective design of experiment (DoE) approach. It is clear
that the three tumor vascular parameters contribute greatly to both passive and magnetically targeted
tumor accumulation but play different roles when nanocarriers are targeted to the tumor with different
strategies. It is concluded that tumor permeability is a rate-limiting factor in both targeting modes.
Diameter and microvessel density inﬂuence passive and magnetic tumor targeting, respectively.
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Conventional anti-cancer agents used in chemotherapies do not
demonstrate predominant tumor speciﬁcity compared to normal
cells. Therapeutic effects largely rely on the general systemic bio-
distribution. Cancer therapy, therefore, is often terminated as a
result of the severe side effects, caused by the therapeutic agents,
before the expected therapeutic outcome is reached [1]. Nano-
technology e.g., nanoparticle-based drug delivery (nanomedicine),
has emerged providing a more efﬁcient targeting to tumors by
passive accumulation which is known as the enhanced perme-
ability and retention (EPR) effect [2].
A recent clinical study showed positive tumor accumulation of
indium-111 radiolabeled PEGylated liposomes in 15 out of 17 pa-
tients employed [3]. The percentage of the injected dose per kg of
tumor (% ID/kg) being taken up by the tumors, varied hugely from
2.7% to 53.0% ID/kg at 72 h, among patients with different or evenl-Jamal).
er Ltd. This is an open access articthe same type of tumor. The study hypothesized that the consid-
erable heterogeneity in the EPR effect was likely due to the het-
erogeneous structural and functional integrity of the tumor
neovasculature [3].
Magnetic targeting has been proven to enhance tumor accu-
mulation to a higher extent than passive targeting. Increased tumor
accumulation of the superparamagnetic iron oxide nanoparticles
(SPIONs) can be achieved when a magnetic ﬁeld is applied to the
targeted site [4]. Concentrating the therapeutic agents at the tumor
site allows higher doses to be administered at reduced systemic
side effects [5]. However, it is expected that not all experimental
subjects will beneﬁt from magnetic targeting therapy to the same
extent due to such differences in EPR [6]. As a result, in addition to
nanoparticle engineering and their physicochemical properties,
there are biological factors to consider in the ﬁeld of passive and
magnetic targeting. It is important to identify the potentially
important parameters that inﬂuence passive and magnetic target-
ing in different types of tumor.
As suggested in some previous studies, the heterogeneity in
tumor vascularization tends to inﬂuence passive accumulation of
nanocarriers in solid tumors [3,6]. No study has been performed sole under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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targeting. In this work, we aimed to understand if tumor vascula-
ture has any inﬂuence on magnetic targeting, in comparison to
passive targeting, and if so, to identify the key parameters. Four
tumor models, of contrasting enhanced permeability and retention
(EPR) effect and vascularization characteristics, were used: colon
(CT26), breast (4T1), lung (Lewis lung carcinoma) cancer and mel-
anoma (B16F10). Three vascular parameters were chosen, namely,
microvessel density, vessel pore size cutoff and vessel diameter. A
retrospective design of experiment (DoE) study was conducted
using the biodistribution data obtained with gamma counting. The
nanocarrier used is a previously developed magnetic nanocapsule
(m-NCs) combined with passive or magnetic targeting approach.
The two main responses studied are %ID/g tumor following passive
(TU-) or magnetic (TUþ) targeting. The results concluded that these
vascular parameters could signiﬁcantly inﬂuence passive and
magnetic targeting to various degrees. Furthermore, taking
advantage of the DoE approach, it was possible to extract mathe-
matic relationship, i.e., equations, to quantify the impact that each
single vascular factor had on passive/magnetic targeting.
2. Materials and methods
2.1. Materials and reagents
‘Ferroﬂuid’ magnetic oil (oleic acid coated SPIONs with a
diameter of 10 nm, suspended in kerosene at 1017 particles per ml)
was purchased from Magnacol Ltd (UK). The constituent oleic acid
coated SPIONs were separated from the kerosene solvent by pre-
cipitation in isopropanol and dried to provide the SPION powder
that was subsequently used in the m-NC formulations. Soybean
lecithin (Epikuron 140 V) was a kind gift from Cargill Pharmaceu-
ticals (USA). Polyoxyethylene-bis-amine (NH2-PEG3.5KDa-NH2) was
purchased from JENKEM (USA). D/L-lactide/glycolide copolymer 75/
25 (PLGA18KDa-COOH) was purchased from Purac Biomaterials
(Netherlands). Tween® 80, nitric acid, methanol, dimethylsulph-
oxide (DMSO) and dichloromethane were obtained from Fisher
Scientiﬁc Ltd (UK). Sodium chloride, phosphate buffered saline
tablets and diethylene triamine pentaacetic acid (DTPA), castor oil
and ethylenediaminetetraacetic acid disodium salt dihydrate
(EDTA) were purchased from Sigma-Aldrich (UK). Advanced Ros-
well Park Memorial Institute (RPMI) medium, penicillin-
streptomycin 100X, Trypsin-EDTA (1X) with Phenol red, Gluta-
max™ supplement, phosphate buffered saline PBS (10X, pH 7.4)
and phosphate buffered saline PBS (1X, pH 7.4) were obtained from
Gibco, Invitrogen (UK). Roswell Park Memorial Institute (RPMI)-
1640 and Dulbecco's modified Eagle's (DMEM) medium were ob-
tained from Sigma Aldrich (UK). Fetal Bovine serum (FBS) was ob-
tained from First-Link Ltd (UK). Disposable square polystyrene
cuvettes and disposable capillary cells were purchased from Mal-
vern Instrument (UK). PD-10 desalting column was obtained from
GE Healthcare Life Sciences (UK).
2.2. Preparation of the m-NCs
The magnetic polymeric nanocapsules (m-NCs) were prepared
by the single emulsiﬁcation/solvent evaporation method [7].
PEGylated PLGA polymer was synthesized as reported previously
[7,8]. Brieﬂy, PLGA18KDa-PEG3.5KDa-NH2 (12.5mg), castor oil (75mg),
soybean lecithin (25 mg) and SPIONs (2.5 mg) were dissolved in
2.5 ml dichloromethane. The organic phase was poured into an
aqueous phase (5 ml) containing Tween® 80 (20 mg) as a hydro-
philic surfactant. The resultant dispersion was emulsiﬁed by ultra-
sonication using a probe sonicator (Soniprep 150, UK) at 15 micro
amplitude for 180 s, in an ice bath. Organic solvents were thenevaporated in a chemical fume hood for 20min. The ﬁnal volume of
the m-NC suspension was adjusted to 5 ml. The obtained m-NC
suspension was further condensed by 20 times, yielding 50 mg/ml
of the polymer.
2.3. Size and zeta potential measurements
The hydrodynamic size (Z-Average), polydispersity index (PDI)
and zeta potential of the products were determined by NanoZS
(Malvern Instrument, UK) at 25 C, using disposable square poly-
styrene cuvettes (for size and PDI) or disposable capillary cells (for
zeta potential). The Z-Average diameter and polydispersity index
were measured in water and presented as the average value of
three measurements, with 15 runs within each measurement. The
zeta potential was also measured in water and presented as the
average value of threemeasurements, with 20e25 runswithin each
measurement. The mean and standard deviation of size and zeta
potential were calculated for each sample.
2.4. Determination of SPION encapsulation efﬁciency in m-NCs
m-NCs were puriﬁed by size exclusion chromatography (G75
column) to remove any non-encapsulated SPIONs. The Fe content
was determined by inductively coupled plasma mass spectrometry
(Perkin Elmer SCIEX ICP mass spectrometer, ELAN DRC 6100, USA).
For ICP-MS measurements, Fe standards (Leeman Labs Inc., MA)
were prepared in 20% nitric acid to obtain a standard curve in the
range of 10e10000 parts per billionwith respect to Fe.m-NCs were
digested in 2 ml of nitric acid and incubated overnight at 50 C. The
resulting solution was diluted by 10 times in water before
measurement.
2.5. Radiolabeling of m-NCs and serum stability studies
To radio-label the m-NCs with indium-111, m-NCs were pre-
pared as described above except that PLGA18KDa-PEG3.5KDa-DTPA
was included at 10% (w/w) of the total polymer content. The m-NC
suspension (50 mg/mL of polymer) was incubated with 2 M
ammonium acetate (one-ninth of the reaction volume, pH 5.5), to
which 1 MBq of 111InCl3 (Mallinckrodt, UK) per injection dose was
added. The reaction was kept at room temperature for 30 min with
intermittent vortexing every 10 min. Upon completion, the radio-
labeling reaction was quenched by the addition of 0.1 M EDTA
chelating solution (one twentieth of the reaction volume). 111InCl3
alone was subjected to the same labeling reaction conditions and
used as a control.
The m-NCs-111In were passed through PD-10 columns (size
exclusion chromatography) before injecting into animals to ex-
change the ammonium acetate buffer (pH 5.5) with PBS (pH 7.4)
and to remove free 111In-EDTA. The m-NCs-111In (~150 mL per in-
jection dose, 25 mg/mL of polymer) were collected from the col-
umn and spotted on instant thin layer chromatography (iTLC) strips
whichwere then developed in 0.1M ammonium acetate containing
50 mM EDTA as a mobile phase. Strips were allowed to dry before
being developed and counted quantitatively using a cyclone
phosphor detector (Packard Biosciences, UK) to ensure that no free
111In-EDTA was present in the injected solution.
2.6. CD31 immunohistochemistry staining
Murine vascular blood vessels were detected using species-
speciﬁc CD31 immunostaining. Unstained tumor sections were
processed after conventional deparafﬁnization and endogenous
peroxidase quenching using 3% hydrogen peroxide. Tumor tissue
sections were incubated with 10% normal donkey serum in PBS for
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anti-mouse CD31 primary antibody (ab28364, Abcam, UK) was
diluted 1: 50 in 2% donkey serum in PBS and incubated for 3 h at
room temperature, followed by incubationwith the secondary anti-
rabbit HRP using an X-Cell-Plus HRP Detection Kit (Menarini Di-
agnostics, UK) for 45 min at room temperature. The reaction was
revealed using a VECTOR SG Peroxidase (HRP) Substrate Kit (Vector
Laboratories, US) for 10 min at room temperature. All sections were
counterstained with Neutral Fast Red (Sigma Aldrich, UK).
2.7. Microvessel density (MVD) assessment
The microvessel density (MVD) in the tumor was estimated as
previously described in the literature [9]. The assessment was
performed using Leica DM2000 light microscope (UK) and images
were required using a Q-capture pro 7 software. Brieﬂy, immuno-
stained tumor sections were initially examined at low magniﬁca-
tion (10X) to locate the highly vascularized areas. Three areas with
the highest number of discrete microvessel proﬁles were selected
subjectively as the hot spot areas. One microscopic ﬁeld was
identiﬁed within each hot spot area and examined at higher
magniﬁcation (20X). All individual microvessel proﬁles within the
applied microscopic ﬁeld were counted according to the generally
accepted criteria reported in the literature [9,10]. These included
any stained individual endothelial cell and clusters separated from
adjacent microvessels or microvessels with or without vascular
lumens. Microvessels in necrotic or sclerotic areas within a tumor
and areas adjacent to the invasive carcinoma were not considered
in the vessel counts. The MVD was deﬁned as the average number
of manually counted vessel of three hot spots per mm2 of tumor
tissue.
2.8. Vessel pore size cutoff (CO) and diameter (DM) assessment
The assessment of CO and DM has been reported in the litera-
ture. In the reported studies, CO in the four tumor types was
determined by assessing the extravasation and tumor accumula-
tion of the radiolabeled liposomes and lipid micelles with different
hydrodynamic sizes. The assessment of CO in CT26/B16F10, 4T1 and
LLC tumors was reported by Ishida et al. [11], Charrois et al. [12] and
Kashiwagi et al. [13], respectively. The liposomes and lipid micelles
were intravenously injected into the tumor-bearing mice and %ID/g
of tumor was quantiﬁed by measuring the radioactivity. The lower
and upper end of the CO range in each type of tumor were deter-
mined when a signiﬁcant increase or reduction in %ID/g of tumor
were observed, respectively, upon increasing the size of the
nanocarrier.
The mean vessel DM values were previously determined by
other groups using CD31 immunoﬂuorescence staining and
confocal microscopy. The assessment of DM in CT26, 4T1, B16F10
and LLC tumors was reported by Fisher et al., Goel et al., Bouvard
et al. and Braun et al. [14e17], respectively. The vessels diameters
were analyzed with either ImageJ (CT26), an in-house MATLAB
algorithm (4T1), Histolab™ software (B16F10) or Fiji software (LLC).
2.9. Radiolabeling of m-NCs and serum stability studies
To radio-label the m-NCs with indium-111, m-NCs were pre-
pared as described above except that PLGA18KDa-PEG3.5KDa-DTPA
was included at 10% (w/w) of the total polymer content. The m-NC
suspension (50 mg/mL of polymer) was incubated with 2 M
ammonium acetate (one-ninth of the reaction volume, pH 5.5), to
which 1 MBq of 111InCl3 (Mallinckrodt, UK) per injection dose was
added. The reaction was kept at room temperature for 30 min with
intermittent vortexing every 10 min. Upon completion, the radio-labeling reaction was quenched by the addition of 0.1 M EDTA
chelating solution (one twentieth of the reaction volume). 111InCl3
alone was subjected to the same labeling reaction conditions and
used as a control.
The m-NCs-111In were passed through PD-10 columns (size
exclusion chromatography) before injecting into animals to ex-
change the ammonium acetate buffer (pH 5.5) with PBS (pH 7.4)
and to remove free 111In-EDTA. The m-NCs-111In (~150 mL per in-
jection dose, 25 mg/mL of polymer) were collected from the col-
umn and spotted on instant thin layer chromatography (iTLC) strips
whichwere then developed in 0.1M ammonium acetate containing
50 mM EDTA as a mobile phase. Strips were allowed to dry before
being developed and counted quantitatively using a cyclone
phosphor detector (Packard Biosciences, UK) to ensure that no free
111In-EDTA was present in the injected solution.2.10. CT26, 4T1, LLC and B16F10 tumor inoculation
All animal experiments were performed in compliance with the
UK Home Ofﬁce (1989) Code of Practice for the Housing and Care of
Animals used in Scientiﬁc Procedures.
CT26 murine colon adenocarcinoma cells (CT26, ATCC®, CRL-
2638™) and B16F10 murine melanoma cells (B16-F10, ATCC® CRL-
6475™) were cultured in Advanced Roswell Park Memorial Insti-
tute (RPMI) 1640 medium. 4T1 murine mammary carcinoma cells
(4T1, ATCC®, CRL-2539™) were cultured in RPMI-1640 medium.
Lewis lung carcinoma cells (LL/2, LLC1, ATCC® CRL-1642™) were
cultured in Dulbecco's modified Eagle's (DMEM) medium. All me-
dia were supplemented with 1% Glutamax™, 1% penicillin-
streptomycin and 10% fetal bovine serum (FBS). DMEM medium
was further supplemented with 1% sodium pyruvate. All cells were
cultured in 5% CO2 and 95% air at 37 C.
CT26 and 4T1 were harvested and re-suspended in PBS solution
(pH 7.4). 1  106 cells in 20 mL were injected subcutaneously and
bifocally at the hind foot of syngeneic female BALB/c mice aged 4e6
weeks (Harlan, UK). The same procedures were performed for LLC
and B16F10 tumor model in syngeneic female C57Bl6 mice aged
4e6 weeks (Harlan, UK). After inoculation, the tumor volume was
measured every other day using a digital caliper and calculated
using Equation (1) [18].
Tumor volume

mm3

¼ 4
3
p

A
2
2B
2

¼ 0:52A2B (1)
where A and B represent the width and the length of the tumors,
respectively. All experiment was carried out (m-NCs administra-
tion) when the tumor volume reached approximately
400 mm3e600 mm3.2.11. Magnetic targeting setup in vivo
Disk-shaped nickel-coated neodymium iron boron (Nd2Fe14B)
magnets (Magnet Expert Ltd, Tuxford, UK) were used for the in vivo
magnetic drug targeting studies. The magnet was 8 mm diameter,
5 mm thick, N42 grade magnet (product code F324), which had a
reported ﬁeld strength of 0.43 T (T) and a reported ‘vertical pull’
parameter (a measure of the mass of material that the magnet
could lift) of 1.9 kg. A single magnet was placed non-invasively over
the surface of one of the bifocal tumors and retained using surgical
tapes. The contralateral tumor was used as an internal negative
control where no magnet was applied. The magnet was then
removed at 1 h post-injection of m-NCs.
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counting
Organ biodistribution, blood circulation and excretion proﬁles of
m-NCs-111Inwere assessed quantitatively in tumor-bearing mice by
gamma counting. Mice were randomly divided into three groups
(n ¼ 3) and assigned as 1 h, 4 h, 24 h group. Mice were injected
intravenously via a lateral tail vein with ~0.7 MBq m-NCs-111In
(150 mL in PBS). Magnetic targeting was applied as described above.
Blood samples (5 mL) were collected from the tail vein at 2 min,
5 min, 10 min, 30 min, 1 h, 4 h and 24 h post-injection. Tumors and
other tissues, i.e., skin, liver, spleen, heart, lung, muscle, bone, brain,
stomach, intestine, tail and carcass were removed, weighed, and
the radioactivity was measured in a gamma counter (1280 Com-
puGamma Universal Gamma Counter, LKB Wallac, Finland), using
the appropriate energy windows for 111In. Results were expressed
as the percentage of injected dose per gram organ/tumor (% ID/g) as
means ± SEM (n ¼ 3).
2.13. Hematoxylin and eosin (H&E) staining of tissue sections
Portions of major organs i.e., heart, lung, kidney, liver, spleen
and tumor tissues were sampled from treated animals, ﬁxed in 10%
neutral buffered formalin. Samples were then wax-embedded and
sectioned for hematoxylin and eosin (H&E) staining according to
standard histological protocols at the Royal Veterinary College, UK.
Unstained sections were processed for immunohistochemistry
staining as will be described.
2.14. Retrospective design of experiment (DoE)
To better understand and visualize which vascular parameters
(Factor 1: MVD; Factor 2: CO; Factor 3: DM) may have had an
impact on magnetic tumor targeting, a retrospective analysis, using
historical biodistribution data in the four murine solid tumor
models, was performed. Response surfaces and the predictive
equations were then established. Raw data used to create the
Predictive Response Surface for Responses 1 (%ID/g TUþ) and 2 (%
ID/g TU-) are summarized in Table S1. Data were analyzed using
Design-Expert 9, v9.0.6.2 (Stat-ease, Inc., USA). Suitable predictive
models for Responses 1 and 2 were achieved using Sequential
Model Sum of Squares (SMSS). A detailed description of the retro-
spective DoE analysis is provided in the Supplementary Materials.
2.15. Statistical analysis
Quantitative data are presented as mean ± standard deviation
(SD) unless speciﬁed as mean ± standard error of the mean (SEM).
One-way ANOVA and Tukey's multiple comparison test were per-
formed using IBM SPSS version 20. Signiﬁcance was taken as
p < 0.05 unless otherwise stated.
3. Results
3.1. Preparation and characterization of magnetic nanocapsules
(m-NCs) for magnetic targeting
The PEGylated oil-cored polymeric magnetic nanocapsules (m-
NCs) capable of encapsulating high amount of SPIONs were pre-
pared using a single emulsiﬁcation/solvent evaporation method, as
we reported previously [7]. The hydrodynamic diameter obtained
for the m-NCs is in the range of 200e210 nm with Zeta potential
of ~ 20 ± 1 mV (Table 1). Cryo-TEM images have previously
conﬁrmed the coredshell structure of the reported m-NCs and
showed that the SPIONs are encapsulated within their core [7].Extensive characterization ofm-NC has been published by the same
authors, and the results demonstrated that this material was pre-
pared successfully. A summary ofm-NC's characterization is shown
in Fig. S1.
3.2. Assessment of tumor vasculature characteristics
Four in vivo murine solid tumor models were employed in this
study: (i) CT26 colon cancer model (colon carcinoma, ﬁbroblast
cells), (ii) 4T1 breast cancer model (mammary gland carcinoma,
epithelial cells), (iii) Lewis Lung Carcinoma (LLC) (lung carcinoma)
and (iv) B16F10 melanoma (spindle-shaped, epithelial-like cells).
The experiment design of this study is illustrated in Fig. 1. The
following vascular parameters were assessed in these four tumor
models to characterize their tumor vascularization:
Microvessel density (MVD). MVD was assessed by histological
examination of CD31 immune-stained tumor sections (Fig. 2a and
Fig. S2). CD31 is an endothelial cell marker, characteristic for blood
vessels [19]. The MVD values were expressed as the number of
blood vessels per mm2. As shown in the immunohistochemistry
staining images, B16F10 tumors, occasionally pigmented with
black/brown melanin granules of different sizes, contained a
number of erythrocyte-ﬁlled, wide, lumen-containing vessels with
clear endothelial linings. CT26 and 4T1 tumors demonstrated much
smaller vessel diameters than those observed in B16F10 tumors.
MVD values for the different tumors are shown in Fig. 2b. A
considerable degree of MVD heterogeneity was found, in the
following order: CT26 (322 ± 56) > 4T1 (221 ± 55) > LLC
(134 ± 54)  B16F10 (101 ± 48).
Blood vessel pore size cutoff (CO). This parameter is indicative of
vessel permeability. CO values reported in the literature for CT26,
4T1 and B16F10 tumor blood vessel pore sizes are in the range of
120e400 nm [11], 154e241 nm [12] and 200e400 nm [11],
respectively. LLC tumors, on the other hand, are known to be less
permeable, with CO between 20 and 100 nm [20]. CO values are
summarized in Fig. 2c.
Blood vessel diameter (DM). The DM of the four tumor types
used in the study are reported in the literature and are summarized
in Fig. 2d. Values ranged between 10.4 and 14.3 mm for CT26 [14],
4T1 [15] and LLC tumors [17]. A larger vessel DM, up to 28 ± 2 mm, is
reported for B16F10 tumors [16].
3.3. Evaluation of blood circulation and organ distribution in vivo
Tumor accumulation of m-NCs in the four murine solid tumor
models was assessed following intravenous (i.v.) administration
using our previous magnetic targeting protocol [7]. PLGA18kDa-
PEG3.5kDa-DTPA (10% w/w) was incorporated into m-NCs, which
was then radiolabeled with the gamma emitter, 111In, to allow
quantitative uptake studies in mice. Blood circulation, excretion,
organ biodistribution and tumor accumulation proﬁles were eval-
uated and compared by gamma counting. Organ uptake was
expressed as the percentage of injected dose per gram of tissue (%
ID/g).
Blood circulation proﬁles are shown in Fig. 3a. Expectedly, m-
NCs exhibited comparable and prolonged blood circulation in all
types of tumor-bearing mice, due to PEGylation ofm-NCs. Values of
~36e42%, 20e27% and 1e3% ID in blood were detected at 1, 4 and
24 h post-injection, respectively. About 40% and 0e2% ID/mouse
were excreted in urine and feces, respectively (Fig. 3b). Similarly, no
differences in organ biodistribution, except tumors, were observed
at 24 h post-injection (Fig. 3c). Earlier time point studies (1 and 4 h)
are shown in Fig. S3.
Conﬁrming our previous ﬁndings in CT26 tumor-bearing mice
[7], spleen (14e19% ID/g), liver (11e14% ID/g) followed by the
Table 1
Physicochemical characterization of PEGylated NCs prepared by single emulsiﬁcation/solvent evaporation method.
Sample Initial SPION loadinga Hydrodynamic size ± SD (nm)b,e PDI ± SDe Zeta potential ± SD (mV)c SPION EE% ± SDd,e
NCs e 203 ± 4 0.12 ± 0.01 45 ± 2 e
m-NCs 1.84% 205 ± 3 0.16 ± 0.01 36 ± 1 95 ± 3
a Values were expressed as w/w SPION/NC. Total NCs weight is calculated by the addition of polymer, lecithin, castor oil, SPIONs and Tween 80® weights.
b Size was measured with dynamic light scattering in deionized water (n ¼ 3).
c Values were obtained with laser Doppler electrophoresis and measured in deionized water.
d Iron content was determined with ICP-MS (n ¼ 3).
e Results are expressed as mean ± SD (n ¼ 3).
Fig. 1. Schematic description of the experimental design. Biodistribution assessment of m-NCs and vascularization characterization in four murine solid tumor models. CT26
(colon), 4T1 (breast) or LLC (lung), B16F10 (melanoma) cells (1  106) were injected subcutaneously (s.c.) and bifocally at the hind foot of female BALB/c (CT26, 4T1) or C57Bl6 mice
(LLC, B16F10). Mice were then intravenously (i.v.) injected with radiolabeled magnetic nanocapsule, m-NC- 111In, when tumors reached volumes ~400e600 mm3. A permanent
magnet was applied to one tumor for 1 h while the other remained unexposed. The percentage injection dose per gram tumors (%ID/g), with (TUþ) or without (TU-) exposure of a
magnetic ﬁeld was assessed with gamma counting. Variables tested are: microvessel density (MVD), vessel pore size cutoff (CO) and vessel diameter (DM).
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sults suggest that m-NCs exhibited matching blood circulation,
elimination and major organ biodistribution proﬁles in all tumor-
bearing mice tested, so any differences in tumor uptake proﬁles
are likely to be tumor type-dependent.3.4. Passive and magnetic targeting of solid tumors in vivo
Magnetic targeting efﬁcacy in the tumors was expressed as fold
increase (TUþ/TU- ratio) in % ID/g tumor, upon the application of an
external magnetic ﬁeld (magnetic targeting, TUþ), compared to
non-magnetically targeted tumors (passive targeting, TU-). The
absolute tumor uptake values obtained at 24 h varied signiﬁcantly
between the different tumor types, under both passive and mag-
netic targeting conditions (Fig. 4a). Values at 1 and 4 h are pre-
sented in Fig. S4. Higher % ID/g tumor values were found for
magnetically targeted (TUþ) than passively targeted tumors (TU-)
in all tumor types tested. In case of passive targeting, the following
order in tumor uptake was obtained: CT26 (2.6 ± 0.2%)  4T1
(2.0 ± 0.2%)  B16F10 (1.8 ± 0.2%) > LLC (1.1 ± 0.3%). For magnet-
ically targeted tumors (TUþ), the following order and values were
obtained: CT26 (5.7 ± 0.2%) (p < 0.05) > B16F10 (3.6 ± 0.3%)  4T1
(3.4 ± 0.4%)  LLC (3.1 ± 0.5%). The TUþ/TU- ratios ranged between
1.8 ± 0.3 and 2.8 ± 0.7 in all tumormodels tested (p > 0.05) (Fig. 4b).
It is worth noting that results presented here were performed
following the whole body saline perfusion so it is unlikely that the
tumor uptake data are inﬂuenced by blood contamination.
Our results conﬁrmed that magnetic targeting does not only
improve uptake in highly vascularized ([MVD) and permeable
([CO) tumors, e.g., B16F10 tumors but poorly vascularized and less
permeable tumors, e.g., LLC tumors, can also beneﬁt from this tar-
geting approach.3.5. Retrospective design of experiment (DoE) analysis
To identify the key vascular characteristics and visualize the
impact of changing vascular multiple parameters on magnetic tu-
mor targeting, we have applied a retrospective design of experi-
ment (DoE) analysis using historical biodistribution data, to
establish the response surfaces and the predictive models. Further
details on DoE studies are in the Supplementary Materials
(Table S1-15 and Fig. S5, Fig. S6). We identiﬁed three quantitative
factors, MVD in number/mm2 (Factor A), mid-point CO values in nm
(Factor B) and mean DM in mm (Factor C), as critical tumor vascu-
larization features to evaluate two responses including %ID/g of TU-
(response 1) %ID/g of TUþ (response 2).
A linear predictive model of the vascular factors on response 1
was found and their mathematical relationship is presented in
Equation (2) and Equation (3), in the coded and actual unit,
respectively. The factors were coded by a linear transformation
from their original measurement scale to a uniﬁed unit to allow
direct comparison between factors with different units. Equation
(2) demonstrated a positive coefﬁcient of 0.43 and a negative co-
efﬁcient of 0.26 for CO and DM, receptively, indicating larger CO
and smaller DM would favor the passive tumor accumulation. The
higher value of the coefﬁcient of CO also suggests that CO is the
rate-limiting step for passive tumor uptake, possibly via inﬂuencing
extravasation. The effect of DM appears to be more pronounced in
more permeable vessels (CO ~ 300 nm) than the less leaky ones
(CO ~ 60 nm) in the surface response plot of response 1 (Fig. 5a).
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ID=gðTU  Þ
p
¼ 1:14þ 0:43B 0:26C (2)
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ID=g ðTU  Þ
p
¼ 0:95221þ ð0:0361277 COÞ
 ð0:019607 DMÞ (3)
Fig. 2. Tumor vasculature characteristics. (A) High and low magniﬁcation microscopic images of H&E stained and anti-CD31 stained tumor sections (400e600 mm3). (B)
Microvessel density (MVD). (C) Average blood vessel's pore size cutoff (CO) and (D) diameter (DM), of all tested tumor models. The MVD in tumors was assessed by immuno-
histochemistry as described in the text. CO and DM values were obtained from Refs. [11,12,20] and [14e17], respectively. For MVD analysis, one-way ANOVA was performed using
IBM SPSS version 20 followed by Tukey's multiple comparison test (*p < 0.05 and ***p < 0.005).
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related vascular factors were factor A (MVD) and factor B (CO), as
shown in Equation (4) and Equation (5) in the coded and actual
unit, respectively. Their linear coefﬁcients were both positive, with
0.31 and 0.22 for MVS and CO, respectively. This indicates that
higherMVD and CO values encourage the accumulation ofm-NCs in
tumors when a magnetic ﬁeld is applied (Fig. 5b).
Ln½ID=gðTU þ Þ ¼ 1:33þ 0:31Aþ 0:22B (4)
Ln½ID=gðTU þ Þ ¼ 0:58464þ ð0:0181518MVDÞ
þ ð0:00182389 COÞ (5)
4. Discussion
Nanocarriers exploit the EPR effect to passively accumulate in
tumors. However, the degree of EPR effect can vary from one tumorto another, or even spatially and temporally within the same tumor
[21]. This heterogeneity in the EPR effect results in differences in
therapeutic response rates [22]. Tumors that are known to be
extensively vascularized and permeable, such as head and neck
cancer, show high therapeutic response rate to Caelyx® (ALZA
Corporation), a liposomal doxorubicin formulation [3,23]. In
contrast, poor therapeutic efﬁcacy was observed in hepatocellular
carcinoma treated with a polymer-doxorubicin conjugate [24].
These studies suggested that the heterogeneous tumor uptake of
nanocarriers was likely related to the differences in the structural
and functional integrity of the tumor neovasculature [3,21].
Vascular parameters, such as tumor angiogenesis, vessel perme-
ability and perfusion, therefore, can lead to a distinct loco-regional
distribution of nanocarriers in the tumor. Harrington et al. showed
that the tumor volume could affect the degree of liposomal passive
accumulation in patients with squamous cell carcinoma of the head
and neck (SCCNH), lung or breast cancers, which was likely due to
the presence of poor vascularized or even necrotic areas in the
tumor [3]. Koukourakis et al. further conﬁrmed that there was a
Fig. 3. Organ biodistribution studies of radiolabeled magnetic nanocapsules in major organs following intravenous administration. Bifocal CT26, 4T1, LLC and B16F10 tumor-
bearing mice were intravenously injected with m-NC-111In, at a dose of 312.5 mg polymer/kg, 125 mg SPION/kg (70 mg Fe/kg). A permanent magnet (0.43 T, 8 mm in diameter) was
applied to one tumor for 1 h. Mice were sacriﬁced at the speciﬁed time point, following whole body saline perfusion. (A) Blood clearance proﬁles, (B) Excretion proﬁles and (C)
Organ biodistribution proﬁles, at 24 h post-injection. Results are expressed as mean ± SEM (n ¼ 3).
Fig. 4. Tumor uptake of radiolabeled magnetic nanocapsules in solid tumors
following intravenous administration. Bifocal CT26, 4T1, LLC and B16F10 tumor-
bearing mice were intravenously injected with m-NC-111In, at a dose of 312.5 mg
polymer/kg, 125 mg SPION/kg (70 mg Fe/kg). A permanent magnet (0.43 T, 8 mm in
diameter) was applied to one tumor (TUþ) for 1 h. The contralateral tumor remained
unexposed (TU-) and was used as a baseline control, for each of the tumor types tested.
Mice were sacriﬁced at the speciﬁed time point, following whole body saline perfu-
sion. (A) The percentage injection dose per gram tumors (%ID/g), with (TUþ) or
without (TU-) exposure of a magnetic ﬁeld, was assessed with gamma counting, at
24 h. (B)Magnetic drug targeting, quantiﬁed by the fold increase in tumor uptake upon
application of magnetic ﬁeld, expressed as TUþ/TU- ratio. Results are expressed as
mean ± SEM (n ¼ 3). One-way ANOVA was performed using IBM SPSS version 20
followed by Tukey's multiple comparison test (**p < 0.01 and ***p < 0.005).
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vessel density in six non-small cell lung cancer patients [23]. Hobbs
et al., on the other hand, suggested that tumors also have tumor-
dependent functional pore size cutoff and macromolecule perme-
ability. The transvascular transport of nanoparticles with sizes
larger than pore size cutoff can be signiﬁcantly restricted [25]. In
addition to passive targeting, differences in magnetic targeting
response were also observed in vivo in different experimental
subjects and Schleich et al. attributed this effect to the variabilities
of tumor vascularization among individuals [6].
Notably, no report today has studied in details the effect of
multiple vascular parameters on tumor accumulation, especially
with magnetic targeting. Since the ﬁrst liposomal anti-cancer
formulation became available on the market, many types of
nanocarriers have achieved outstanding in vitro and in vivo pre-
clinical performance, have failed the clinical trial stage. This work
aims to understand which tumor vascular parameter(s) can inﬂu-
ence the degree of nanocarriers uptake in tumors, under both
passive and magnetic targeting conditions. This has been achieved
by performing pre-clinical in vivo biodistribution studies, of a
previously reported magnetic-responsive nanocarrier, in mice
bearing different types of tumors. The experimental data was then
combined this with the DoE approach, to generate mathematical
equations. These mathematical equations can assess, in a param-
eter by parameter fashion, the direct link between each of the
vascular factors and the response, in this case, tumor uptake.
Our study showed comparable organ biodistribution, blood
circulation and excretion of m-NCs in the four murine solid tumor
models. Distinct tumor accumulation proﬁles, under both passive
and magnetic targeting conditions, were however obtained. The
differences in vascularization of tumor tissues are likely to have
inﬂuenced the tumor accumulation of m-NCs. Tumor angiogenesis
is related to high microvessel density (MVD) and it is one of the
Fig. 5. Predicting the inﬂuence of the tumor vascular parameters on magnetic
targeting with the retrospective design of experiment (DoE) analysis approach.
Factors tested are factor A: microvessel density (MVD), factor B: vessel pore size cutoff
(CO) and factor C: and vessel diameter (DM). Responses are Response 1: %ID/g TU- and
Response 2: %ID/g TUþ). (A) and (B) show Predictive Response Surface for Response 1
and Response 2, respectively. The DoE analysis was performed using Design-Expert 9,
v9.0.6.2 software.
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plays a prognostic role in determining cancer malignancies such as
metastatic rate [27], tumor angiogenesis [28] and even clinical
therapeutic outcomes [29e31]. This is due to the fact that differ-
ences in tumorMVD, as a result of drastic differences in the number
of blood vessels, can lead to differences in nanocarrier distribution
and accumulation in tumors. MVD counting has been the standard
approach for several decades for vascular analysis. The MVD was
assessed by immunohistochemistry staining in our study with
variable degrees of MVD observed among the four tumor models
tested. CT 26 showed the highest MVD which was 1.5, 2.4 and 3.2-
fold higher than the MVD values observed in 4T1, LLC and B16F10
tumors, respectively.
Tumor vessel permeability is another parameter considered in
this study since it can remarkably affect the rate of cancer growth,
predisposition to metastasis and delivery of macromolecular ther-
apeutics to tumor cells [32]. Tumor vasculature is reported to be
leaky and permeable with endothelial defects. There is a minimal
vessel pore size cutoff (CO) required for nanocarriers to extravasate.
Hobbs et al. demonstrated that the pore sizes of tumor blood ves-
sels were highly dependent on the tumor model type and the
anatomical location of tumor inoculation. Most murine tumors
inoculated subcutaneously exhibited a pore size cutoff ranging
between 380 and 780 nm (as large as 1.2e2 mm in one tumor type)
[25]. Tumors with small CO tend to have a very limited permeability
to macromolecules and consequently low extravasation of nano-
carriers. In the four murine solid tumor models tested here, the
blood vessels in LLC tumors were signiﬁcantly less permeable(3e5-fold smaller CO, mid-point values) than in other types [11,12].
Weissig et al. observed that micelles with 20 nm achieved higher
accumulation in LLC tumor compared to liposomes of 100 nm in
size, despite the longer blood circulation time of the latter. This
agrees with our ﬁndings here that LLC tumors also showed the least
uptake in passive and magnetically targeted.
Another important vascular parameter in passive delivery is the
vessel diameter (DM). DM affects tumor tissue perfusion and blood
ﬂow distribution, thus, can potentially affect drug delivery and the
therapeutic outcomes [33]. For example, large DM results in
reduced vascular surface to plasma volume ratio which therefore
reduces the possibility of nanocarriers to reach and pass through
the blood vessel wall [34]. Previous studies suggested that blood
vessels of B16F10 tumors are 2e3-fold larger than vessels of the
other three models [13e15,17]. Our histological observations are in
line with the reported results where B16F10 melanoma tumors
showed vessels with the large lumen, ﬁlled with erythrocytes. One,
therefore, may expect that the larger diameter of blood vessels in
B16F10 tumors should theoretically result in signiﬁcantly smaller %
ID/g for passively targeted B16F10 than CT26 tumors. The gamma
counting showed no signiﬁcant differences in %ID/g TU- between
these two models. This could be due to the highest permeability
reported for B16F10 tumors compared to all other tumor types
tested (mid-point CO values: B16F10 > CT26 > 4T1 > LLC).
In order to single out the effect that each of the vascular pa-
rameters may have had on passive and magnetic targeting, tumor
uptake values obtained in our study with gamma counting i.e., re-
sponses, were ﬁtted into a retrospective DoE analysis. CO has been
shown as the rate limiting step in both targeting modes. This is
already known for passive targeting. Magnetic dragging forces can
enhance passive targeting further by concentrating the nano-
carriers within the tumor and increase their possibility of extrav-
asation. It is logical that they are still unable to extravasate if the
blood vessels are not leaky enough [35].
The DoE analysis for magnetic targeting (Response 2) indicated
that the accumulation of m-NCs in tumor tissues, under the inﬂu-
ence of an external magnetic ﬁeld, was also signiﬁcantly affected by
MVD, in a positive manner. CT26 tumors exhibited highest MVD
and highest TU þ uptake. The high local MVD provides a higher
total surface area available for extravasation of nanoparticles into
tumor interstitium [36e39]. Interestingly, DM has not negatively
inﬂuenced magnetic targeting (p > 0.05). The effect of large DM
could have been overcome by the local increase in the nanocarrier
concentration within the tumor vasculature, due to the acting
magnetic forces, thus compensating for the loss in the vascular
surface area available to extravasation.
As the DoE results imply, the tumor vasculature factors which
appeared to be signiﬁcant, i.e., can inﬂuence %ID/g, were different
between passive and magnetic tumor targeting; CO and DM were
signiﬁcant factors for passive targeting (Table S2, Equations (2) and
(3)), while MVD and CO were signiﬁcant factors for magnetic tar-
geting (Table S9, Equation (4) and (5).
Patient selection, based on their tumor vasculature character-
istics, can become an important factor to consider when selecting
patients for magnetically targeted therapies. In passive tumor tar-
geting, for example, larger CO results in higher %ID/g whereas the
DM can inversely, but mildly, affect %ID/g (Equation (2)). LLC tumor
has the lowest COwhich resulted in the lowest %ID/g TU- compared
to other tumor types. CT26 and B16F10 have large CO but CT26 has
a smaller DM than B16F10 hence CT26 achieved the higher %ID/g
TU- than B16F10 and also other tumors.
When the magnetic ﬁeld was applied, MVD appears to be the
major contributing factor towards %ID/g tumor, with CO comes
second (Equation (4)). The true value coefﬁcient for MVD is ~10
times higher than CO (Equation (5)). LLC tumor, for example, has a
K.-C. Mei et al. / Biomaterials 106 (2016) 276e285284moderate MVD value and managed to achieve a 4-fold increase in
tumor uptake with magnetic targeting, i.e., TUþ/TU- ratio (Fig. 4),
despite its lowest CO value. The DoE provides a good rationale why
LLC achieved the highest improvement with magnetic targeting
despite its lowest %ID/g TU-. Overall, the DoE results provide a
mathematical tool to predict optimal therapeutic outcomes, using
magnetic targeting, knowing the tumor vasculature characteristics
of the solid tumor to be treated. Another positive insight from this
data is that even tumors with low CO but of large DM, and
moderate-to-high MVD are very likely to beneﬁt from magnetic
targeting based therapy.
In addition to biological factors, one may propose that the effect
of physical parameters such as nanoparticle size among others is
interesting to study using the DoE approach. It is however
conceivable that such parameters are likely to alter NP's pharma-
cokinetic proﬁles and interactions with the tumor, introducing
multi-factorial interactions. This type of experiments involving
multi-factorial interactions can be combined with DoE approach
but requires a new experimental design altogether and cannot be
done retrospectively using this set of data. On this relevant topic
and in a very recent work by our group [40,41], we have performed
extensive studies, not involving DoE design, investigating the effect
of increasing SPION loading of the nanocapsule, while maintaining
the same nanocapsule size, on blood circulation time, organ bio-
distribution and tumor targeting in CT26 tumor model. A linear
increase in magnetic targeting as a function of increased SPION
dose was found. No difference in organ biodistribution or blood
circulation time was observed among the m-NC formulations,
containing different amounts of SPION, up to 125 mg/kg dose, a
dose abovewhich an increased liver and spleen uptake and reduced
blood circulation times started to be observed. Magnetic targeting
efﬁciency plateaued at that SPION dose. The stability of our
formulation in presence of serum has also been established [41].
5. Conclusions
The novelty of this work relies on investigating the effect of
biological parameters of solid tumors, onmagnetic targeting, which
has only been studied in the context of passive tumor targeting to
date. In addition, the DoE approach was used to extract mathe-
matical relationship to quantify the impact that each single vascular
factor had on passive/magnetic targeting. These studies are
important as they shed light on which tumor types are likely to be
suitable for magnetic targeting therapy. We have proven here that
the important biological factors can be different in magnetic tar-
geting from those reported to be relevant to passive tumor
targeting.
Our study concerned establishing a correlation between tumor
vascular parameters and degree of tumor uptake following passive
and magnetic targeting. The results suggested that CO was a rate
limiting factor in both targeting modes. DM and MVD inﬂuenced
passive and magnetic targeting, respectively. Our study demon-
strated in mathematical terms that the inﬂuence of an individual
vascular parameter had on the passive and magnetic targeting of
magnetic nanocarriers to tumors. In addition, the ﬁndings of this
study further conﬁrmed the importance of taking the tumor
vasculature characteristics into account when designing nano-
carriers for both passive and magnetic targeting. In relevance to
clinical applications, our results conﬁrmed that the magnetic tar-
geting approach can be applied to both leaky and less leaky tumors.
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